Exact Mass: 459.1828

Exact Mass Matches: 459.1828

Found 500 metabolites which its exact mass value is equals to given mass value 459.1828, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

5-Methyltetrahydrofolic acid

(2R)-2-[(4-{[(2-amino-5-methyl-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl)methyl]amino}phenyl)formamido]pentanedioic acid

C20H25N7O6 (459.1866)

5 methyltetrahydrofolic acid (5-MTHF) is the most biologically active form of the B-vitamin known as folic acid, also known generically as folate. 5-MTHF functions, in concert with vitamin B12, as a methyl-group donor involved in the conversion of the amino acid homocysteine to methionine. Methyl (CH3) group donation is vital to many bodily processes, including serotonin, melatonin, and DNA synthesis. Therapeutically, 5-MTHF is instrumental in reducing homocysteine levels, preventing neural tube defects, and improving vascular endothelial function. Research on folate supplementation suggests it plays a key role in preventing cervical dysplasia and protecting against neoplasia in ulcerative colitis. Folic acid also shows promise as part of a nutritional protocol to treat vitiligo, and may reduce inflammation of the gingiva. Furthermore, certain neurological, cognitive, and psychiatric presentations may be secondary to folate deficiency. Such presentations include depression, peripheral neuropathy, myelopathy, restless legs syndrome, insomnia, dementia, forgetfulness, irritability, endogenous depression, organic psychosis, and schizophrenia-like syndromes. After ingestion, the process of conversion of folic acid to the metabolically active coenzyme forms is relatively complex. Synthesis of the active forms of folic acid requires several enzymes, adequate liver and intestinal function, and adequate supplies of riboflavin (B2), niacin (B3), pyridoxine (B6), zinc, vitamin C, and serine. After formation of the coenzyme forms of the vitamin in the liver, these metabolically active compounds are secreted into the small intestine with bile (the folate enterohepatic cycle), where they are reabsorbed and distributed to tissues throughout the body. Human pharmacokinetic studies indicate folic acid has high bioavailability, with large oral doses of folic acid substantially raising plasma levels in healthy subjects in a time and dose dependent manner. Red blood cells (RBCs) appear to be the storage depot for folic acid, as RBC levels remain elevated for periods in excess of 40 days following discontinuation of supplementation. Folic acid is poorly transported to the brain and rapidly cleared from the central nervous system. The primary methods of elimination of absorbed folic acid are fecal (through bile) and urinary. Despite the biochemical complexity of this process, evidence suggests oral supplementation with folic acid increases the bodys pool of 5-MTHF in healthy individuals. However, enzyme defects, mal-absorption, digestive system pathology, and liver disease can result in impaired ability to activate folic acid. In fact, some individuals have a severe congenital deficiency of the enzyme Methyl tetrahydrofolate reductase (5-MTHFR), which is needed to convert folic acid to 5-MTHF. Milder forms of this enzyme defect likely interact with dietary folate status to determine risk for some disease conditions. In individuals with a genetic defect of this enzyme (whether mild or severe), supplementation with 5- MTHF might be preferable to folic acid supplementation. (PMID: 17176169). 5 methyltetrahydrofolic acid (5-MTHF) is the most biologically active form of the B-vitamin folic acid, also known generically as folate. 5-MTHF functions, in concert with vitamin B12, as a methyl-group donor involved in the conversion of the amino acid homocysteine to methionine. Methyl (CH3) group donation is vital to many bodily processes, including serotonin, melatonin, and DNA synthesis. Therapeutically, 5-MTHF is instrumental in reducing homocysteine levels, preventing neural tube defects, and improving vascular endothelial function. Research on folate supplementation suggests it plays a key role in preventing cervical dysplasia and protecting against neoplasia in ulcerative colitis. Folic acid also shows promise as part of a nutritional protocol to treat vitiligo, and may reduce inflammation of the gingiva. Furthermore, certain neurological, cognitive, and psychiatric presentations may be secondary to folate deficiency. Such presentations include depression, peripheral neuropathy, myelopathy, restless legs syndrome, insomnia, dementia, forgetfulness, irritability, endogenous depression, organic psychosis, and schizophrenia-like syndromes. After ingestion, the process of conversion of folic acid to the metabolically active coenzyme forms is relatively complex. Synthesis of the active forms of folic acid requires several enzymes, adequate liver and intestinal function, and adequate supplies of riboflavin (B2), niacin (B3), pyridoxine (B6), zinc, vitamin C, and serine. After formation of the coenzyme forms of the vitamin in the liver, these metabolically active compounds are secreted into the small intestine with bile (the folate enterohepatic cycle), where they are reabsorbed and distributed to tissues throughout the body. Human pharmacokinetic studies indicate folic acid has high bioavailability, with large oral doses of folic acid substantially raising plasma levels in healthy subjects in a time and dose dependent manner. Red blood cells (RBCs) appear to be the storage depot for folic acid, as RBC levels remain elevated for periods in excess of 40 days following discontinuation of supplementation. Folic acid is poorly transported to the brain and rapidly cleared from the central nervous system. The primary methods of elimination of absorbed folic acid are fecal (through bile) and urinary. Despite the biochemical complexity of this process, evidence suggests oral supplementation with folic acid increases the bodys pool of 5-MTHF in healthy individuals. However, enzyme defects, mal-absorption, digestive system pathology, and liver disease can result in impaired ability to activate folic acid. In fact, some individuals have a severe congenital deficiency of the enzyme Methyl tetrahydrofolate reductase (5-MTHFR), which is needed to convert folic acid to 5-MTHF. Milder forms of this enzyme defect likely interact with dietary folate status to determine risk for some disease conditions. In individuals with a genetic defect of this enzyme (whether mild or severe), supplementation with 5- MTHF might be preferable to folic acid supplementation. (PMID: 17176169) [HMDB] 5-Methyltetrahydrofolic acid (5-Methyl THF) is a biologically active form of folic acid. 5-Methyltetrahydrofolic acid is a methylated derivate of tetrahydrofolate. 5-Methyltetrahydrofolic acid is the predominant natural dietary folate and the principal form of folate in plasma and cerebrospinal fluid[1]. Levomefolic acid (5-MTHF) is an orally active, brain-penetrant natural active form of folic acid and is one of the most widely used folic acid food supplements[1][2].

Doronine

Doronine; 4,8-Secosenecionan-8,11,16-trione, 15,20-dihydro-12-(acetyloxy)-20-chloro-15-hydroxy-4-methyl-

C21H30ClNO8 (459.166)

T 2636C

Antibiotic T 2636C

C25H33NO7 (459.2257)

Hytrin

Terazosin hydrochloride dihydrate

C19H30ClN5O6 (459.1885)

C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D000089162 - Genitourinary Agents > D064804 - Urological Agents Terazosin hydrochloride dihydrate is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride dihydrate works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride dihydrate has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment[1][2][3].

5-Methyltetrahydrofolate

5-methyltetrahydrofolic acid disodium salt

C20H25N7O6 (459.1866)

COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS 5-Methyltetrahydrofolic acid (5-Methyl THF) is a biologically active form of folic acid. 5-Methyltetrahydrofolic acid is a methylated derivate of tetrahydrofolate. 5-Methyltetrahydrofolic acid is the predominant natural dietary folate and the principal form of folate in plasma and cerebrospinal fluid[1].

Narceinone

6-(2-{6-[2-(dimethylamino)ethyl]-4-methoxy-2H-1,3-benzodioxol-5-yl}-2-oxoacetyl)-2,3-dimethoxybenzoic acid

C23H25NO9 (459.1529)

Narceinone is found in opium poppy. Narceinone is an alkaloid from unlanced dried capsules of Papaver somniferum (opium poppy). Alkaloid from unlanced dried capsules of Papaver somniferum (opium poppy). Narceinone is found in opium poppy.

Apixaban

1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-1H,4H,5H,6H,7H-pyrazolo[3,4-c]pyridine-3-carboxamide

C25H25N5O4 (459.1906)

B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AF - Direct factor xa inhibitors C78275 - Agent Affecting Blood or Body Fluid > C263 - Anticoagulant Agent > C173067 - Direct Factor Xa Inhibitor C78275 - Agent Affecting Blood or Body Fluid > C263 - Anticoagulant Agent > C180619 - Direct Oral Anticoagulant D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015842 - Serine Proteinase Inhibitors D006401 - Hematologic Agents > D000925 - Anticoagulants > D000991 - Antithrombins COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

2-[(1S,2S,4R)-2-Hydroxy-7,7-dimethyl-1-(spiro[indene-1,4'-piperidine]-1'-ylsulfonylmethyl)-2-bicyclo[2.2.1]heptanyl]acetic acid

2-[(1S,2S,4R)-2-Hydroxy-7,7-dimethyl-1-(spiro[indene-1,4-piperidine]-1-ylsulphonylmethyl)-2-bicyclo[2.2.1]heptanyl]acetic acid

C25H33NO5S (459.2079)

Diacylglycerol kinase inhibitor i

6-(2-{4-[(4-fluorophenyl)(phenyl)methylidene]piperidin-1-yl}ethyl)-7-methyl-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one

C27H26FN3OS (459.1781)

D004791 - Enzyme Inhibitors R 59-022 (DKGI-I) is a DGK inhibitor (IC50: 2.8 μM). R 59-022 inhibits the phosphorylation of OAG to OAPA. R 59-022 is a 5-HT Receptor antagonist, and activates protein kinase C (PKC). R 59-022 potentiates thrombin-induced diacylglycerol production in platelets and inhibits phosphatidic acid production in neutrophils[1][2][3][4].

Fenoverine

2-{4-[(2H-1,3-benzodioxol-5-yl)methyl]piperazin-1-yl}-1-(10H-phenothiazin-10-yl)ethan-1-one

C26H25N3O3S (459.1617)

A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03A - Drugs for functional gastrointestinal disorders D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent

Levomefolic acid

2-[(4-{[(4-hydroxy-2-imino-5-methyl-1,2,5,6,7,8-hexahydropteridin-6-yl)methyl]amino}phenyl)formamido]pentanedioic acid

C20H25N7O6 (459.1866)

5-methyl-tetrahydrofolate, also known as 5-methyltetrahydrofolate, (l-glu)-(R)-isomer or L-methylfolate, is a member of the class of compounds known as tetrahydrofolic acids. Tetrahydrofolic acids are heterocyclic compounds based on the 5,6,7,8-tetrahydropteroic acid skeleton conjugated with at least one L-glutamic acid unit. 5-methyl-tetrahydrofolate is practically insoluble (in water) and an extremely strong acidic compound (based on its pKa). 5-methyl-tetrahydrofolate can be found in a number of food items such as radish (variety), millet, devilfish, and babassu palm, which makes 5-methyl-tetrahydrofolate a potential biomarker for the consumption of these food products. 5-Methyltetrahydrofolic acid (5-Methyl THF) is a biologically active form of folic acid. 5-Methyltetrahydrofolic acid is a methylated derivate of tetrahydrofolate. 5-Methyltetrahydrofolic acid is the predominant natural dietary folate and the principal form of folate in plasma and cerebrospinal fluid[1].

Lilly 117018

6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl 4-[2-(1-pyrrolidinyl)ethoxy] phenyl ketone

C27H25NO4S (459.1504)

D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D020847 - Estrogen Receptor Modulators D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists

Methyltetrahydrofolate

2-[(4-{[(2-amino-4-oxo-5,6,7,8-tetrahydro-3H-pteridin-6-yl)methyl]amino}phenyl)formamido]-5-methoxy-5-oxopentanoic acid

C20H25N7O6 (459.1866)

Methyltetrahydrofolic acid

2-[(4-{[(2-amino-4-oxo-5,6,7,8-tetrahydro-3H-pteridin-6-yl)methyl]amino}phenyl)formamido]-4-methylpentanedioic acid

C20H25N7O6 (459.1866)

Pavinetant

3-Methanesulphonamido-2-phenyl-N-(1-phenylpropyl)quinoline-4-carboximidic acid

C26H25N3O3S (459.1617)

Methylcysteine sulfoxide

2-(methylamino)-3-sulfanylpropanoic acid; 5-[2-(octane-1-sulfinyl)propyl]-2H-1,3-benzodioxole

C22H37NO5S2 (459.2113)

Methylcysteine sulfoxide is practically insoluble (in water) and an extremely weak basic (essentially neutral) compound (based on its pKa). Methylcysteine sulfoxide can be found in soft-necked garlic, which makes methylcysteine sulfoxide a potential biomarker for the consumption of this food product.

4-hydroxy-2-nonenal-glutathione conjugate

[1-carboxylato-3-({1-[(carboxylatomethyl)carbamoyl]-2-[(4-hydroxy-1-oxononan-3-yl)sulfanyl]ethyl}carbamoyl)propyl]azaniumyl

C19H29N3O8S (459.1675)

4-hydroxy-2-nonenal-glutathione conjugate is a member of the class of compounds known as oligopeptides. Oligopeptides are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds. 4-hydroxy-2-nonenal-glutathione conjugate is practically insoluble (in water) and a moderately acidic compound (based on its pKa). 4-hydroxy-2-nonenal-glutathione conjugate can be found in a number of food items such as vanilla, kale, beech nut, and summer grape, which makes 4-hydroxy-2-nonenal-glutathione conjugate a potential biomarker for the consumption of these food products.

6-hydroxy-galanthindole 6-O-beta-D-glucopyranoside|6-hydroxy-galanthindolyloside A

C23H25NO9 (459.1529)

haterumaimide A

C22H31Cl2NO5 (459.1579)

ADOT

C23H25NO9 (459.1529)

aegelinoside A

C24H29NO8 (459.1893)

6-{[6-(2-Dimethylamino-aethyl)-4-methoxy-benzo[1,3]dioxol-5-yl]-acetyl}-2,3-dimethoxy-benzoesaeure-methylester|6-{[6-(2-dimethylamino-ethyl)-4-methoxy-benzo[1,3]dioxol-5-yl]-acetyl}-2,3-dimethoxy-benzoic acid methyl ester|longicine|narceine methyl ester

6-{[6-(2-Dimethylamino-aethyl)-4-methoxy-benzo[1,3]dioxol-5-yl]-acetyl}-2,3-dimethoxy-benzoesaeure-methylester|6-{[6-(2-dimethylamino-ethyl)-4-methoxy-benzo[1,3]dioxol-5-yl]-acetyl}-2,3-dimethoxy-benzoic acid methyl ester|longicine|narceine methyl ester

C24H29NO8 (459.1893)

rel-(5aR,6R,12S,14aR)-12-[(1R)-1,2-dihydroxy-2-methylpropyl]-1,2,3,5a,6,11,12,14a-octahydro-5a-hydroxy-6,9-dimethoxy-5H,14H-pyrrolo[1,2:4,5]pyrazino[1,2:1,6]pyrido[3,4-b]indole-5,14-dione|rel-(8S,19S)-19,20-dihydro-9,19,20-trihydroxy-8-methoxy-9-epi-fumitremorgin C

rel-(5aR,6R,12S,14aR)-12-[(1R)-1,2-dihydroxy-2-methylpropyl]-1,2,3,5a,6,11,12,14a-octahydro-5a-hydroxy-6,9-dimethoxy-5H,14H-pyrrolo[1,2:4,5]pyrazino[1,2:1,6]pyrido[3,4-b]indole-5,14-dione|rel-(8S,19S)-19,20-dihydro-9,19,20-trihydroxy-8-methoxy-9-epi-fumitremorgin C

C23H29N3O7 (459.2005)

daphmanidin C

C25H33NO7 (459.2257)

haterumaimides K

C22H31Cl2NO5 (459.1579)

2-Deoxydadenosine,9CI,8CI-3,5-dibenzoyl

C24H21N5O5 (459.1543)

R 59-022

diacylglycerol kinase inhibitor i

C25H30ClNO5 (459.1812)

D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist D003879 - Dermatologic Agents > D000982 - Antipruritics D018926 - Anti-Allergic Agents Clemastine (HS-592) fumarate is a selective histamine H1 receptor antagonist. Clemastine fumarate is an antihistamine mainly used for relieving symptoms of allergic reactions primarily by competing with histamine to bind H1 receptors. Anti-inflammatory effects[1][2].

(2S)-2-{[(2S)-1-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-carboxypropanoyl]pyrrolidin-2-yl]formamido}butanedioic acid

C17H25N5O10 (459.1601)

C22H29N5O6 (459.2118)

(2S)-2-{[(2S)-1-[(2S,3R)-2-[(2S)-2-amino-4-carbamoylbutanamido]-3-hydroxybutanoyl]pyrrolidin-2-yl]formamido}butanedioic acid

C18H29N5O9 (459.1965)

(S)-2-(3-(benzyloxy)-4-nitrobenzamido)-3-(1H-indol-3-yl)propanoic acid

C25H21N3O6 (459.143)

Narceinone

6-(2-{6-[2-(dimethylamino)ethyl]-4-methoxy-2H-1,3-benzodioxol-5-yl}-2-oxoacetyl)-2,3-dimethoxybenzoic acid

C23H25NO9 (459.1529)

icas#15

9R-(3R-hydroxy-5R-O-(1H-indol-3-ylcarbonyl)-6S-methyl-(2H)- tetrahydropyran-2-yloxy)-2E-decenoic acid

C25H33NO7 (459.2257)

A 4-O-(1H-indol-3-ylcarbonyl)ascaroside derived from (2E,9R)-9-hydroxydec-2-enoic acid. It is a metabolite of the nematode Caenorhabditis elegans.

icos#15

10-(3R-hydroxy-5R-O-(1H-indol-3-ylcarbonyl)-6S-methyl-(2H)-tetrahydropyran-2-yloxy)-2E-decenoic acid

C25H33NO7 (459.2257)

A 4-O-(1H-indol-3-ylcarbonyl)ascaroside derived from (2E)-10-hydroxydec-2-enoic acid. It is a metabolite of the nematode Caenorhabditis elegans.

5-Methyl-7-[3-(trifluoromethyl)phenyl]-N-(3,4,5-trimethoxyphenyl)imidazo[5,1-f][1,2,4]triazin-2-amine

C22H20F3N5O3 (459.1518)

2-(2-ethoxy-5-piperidin-1-ylsulfonylphenyl)-5-methyl-7-propyl-1H-imidazo[5,1-f][1,2,4]triazin-4-one

C22H29N5O4S (459.194)

HBPipU

C17H24F6N5OP (459.1623)

(3S,4S)-TERT-BUTYL 3-ETHOXY-4-(2-(3-(TRIFLUOROMETHYL)BENZAMIDO)ACETAMIDO)PYRROLIDINE-1-CARBOXYLATE

C21H28F3N3O5 (459.1981)

A-D-GLUCOPYRANOSIDE,METHYL2-DEOXY-2-[[(PHENYLMETHOXY)CARBONYL]AMINO]-3-O-(PHENYLMETHYL)-,6-ACETATE

C24H29NO8 (459.1893)

Fmoc-D-Glu(OBzl)-OH

C27H25NO6 (459.1682)

Fluazacort

C25H30FNO6 (459.2057)

C26H25N3O3S (459.1617)

C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist > C142789 - Neurokinin-3 Receptor Antagonist Pavinetant (MLE-4901) is a neurokinin-3 receptor (NK3R) antagonist.

Terramycin-X

C23H25NO9 (459.1529)

Phenylalanyl-phenylalanyl-phenylalanine

C27H29N3O4 (459.2158)

(2E)-10-{[3,6-dideoxy-4-O-(1H-indol-3-ylcarbonyl)-alpha-L-arabino-hexopyranosyl]oxy}dec-2-enoic acid

C25H33NO7 (459.2257)

9R-(3R-hydroxy-5R-O-(1H-indol-3-ylcarbonyl)-6S-methyl-(2H)-tetrahydropyran-2-yloxy)-2E-decenoic acid

C25H33NO7 (459.2257)

L-Aspartic acid, L-tyrosyl-L-tyrosyl-

C22H25N3O8 (459.1642)

N-[(5R,14R)-5-Amino-5,14-dimethyl-4-oxo-3-oxa-18-azatricyclo[15.3.1.1~7,11~]docosa-1(21),7(22),8,10,17,19-hexaen-19-YL]-N-methylmethanesulfonamide

C24H33N3O4S (459.2192)

Fenoverine

5-Methyltetrahydrofolic acid

(2R)-2-[(4-{[(2-amino-5-methyl-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl)methyl]amino}phenyl)formamido]pentanedioic acid

C24H29NO8 (459.1893)

ST 23:5;O5;Gly

C25H33NO7 (459.2257)

ST 18:3;O6;Tau

C20H29NO9S (459.1563)

ST 19:2;O5;Tau

C21H33NO8S (459.1927)

ST 23:6;O2;Tau

C25H33NO5S (459.2079)

CZ415

C22H29N5O4S (459.194)

CZ415 is a potent and highly selective mTOR inhibitor with a pIC50 of 8.07. CZ415 inhibits mTORC1 and mTORC2 protein complex. CZ415 is a potent and highly selective mTOR inhibitor with a pIC50 of 8.07. CZ415 inhibits mTORC1 and mTORC2 protein complex.

IDH1 Inhibitor 7

(1r,4s,6r,7r,11z)-4-[(1r)-1-chloroethyl]-4-hydroxy-6,7,14-trimethyl-3,8,17-trioxo-2,9-dioxa-14-azabicyclo[9.5.1]heptadec-11-en-7-yl acetate

C21H30ClNO8 (459.166)

{[(2r,3r,4s,5r,6r)-6-{[(3as,7r,7as)-7-hydroxy-5-methyl-4-oxo-3h,3ah,6h,7h,7ah-imidazo[4,5-c]pyridin-2-yl]amino}-5-(2-amino-n-methylacetamido)-4-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy}methanimidic acid

{[(2r,3r,4s,5r,6r)-6-{[(3as,7r,7as)-7-hydroxy-5-methyl-4-oxo-3h,3ah,6h,7h,7ah-imidazo[4,5-c]pyridin-2-yl]amino}-5-(2-amino-n-methylacetamido)-4-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy}methanimidic acid

C17H29N7O8 (459.2078)

{[(2s,3r,4r,5r,6r)-6-{[(3as,7r,7as)-7-hydroxy-5-methyl-4-oxo-3h,3ah,6h,7h,7ah-imidazo[4,5-c]pyridin-2-yl]amino}-5-(2-amino-n-methylacetamido)-4-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy}methanimidic acid

{[(2s,3r,4r,5r,6r)-6-{[(3as,7r,7as)-7-hydroxy-5-methyl-4-oxo-3h,3ah,6h,7h,7ah-imidazo[4,5-c]pyridin-2-yl]amino}-5-(2-amino-n-methylacetamido)-4-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy}methanimidic acid

C23H25NO9 (459.1529)